Pathology and drug action in schizophrenia: Insights from molecular biology

Essays in Biochemistry

Volumn 33, Issue , 1998, Pages 105-116

  Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DOPAMINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN RECEPTOR;

BRAIN; CHEMISTRY; DRUG EFFECT; GENETIC LINKAGE; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; HUMANS; LINKAGE (GENETICS); NEUROTRANSMITTER AGENTS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 0032234618     PISSN: 00711365     EISSN: None     Source Type: Journal    
DOI: 10.1042/bse0330105     Document Type: Article

References (40)

1. Strange, P.G. (1992) Brain Biochemistry and Brain Disorders, Oxford University Press, Oxford
2. Liddle, P.F. (1987) The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br. J. Psychiatry 151, 145-151
3. Andreasen, N.C. (1994) The mechanism of schizophrenia. Curr. Opin. Neurobiol. 4, 245-251
4. Cannon, M. & Jones, P. (1996) Schizophrenia. J. Neurol. Neurosurg. Psychiatry 61, 604-613
5. Seeman, P. & Niznik, H.B. (1990) Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J. 4, 2737-2744
6. 4 receptors in the action and development of antipsychotic drugs. Drugs 51, 7-11
7. Sedvall, G. & Farde, L. (1995) Chemical brain anatomy in schizophrenia. Lancet 346, 743-749
8. & Davis, K.L., Kahn, R.S., Ko, G. & Davidson, M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148, 1474-1486
9. Reith, J., Benkelfat, C., Sherwin, A., Yasuhan, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., Dyre, S.E., et al. (1994) Elevated dopa decarboxylase activity in living brains of patients with psychosis. Proc. Natl. Acad. Sci. U.S.A. 91, 11651-11654
10. Laruelle, M., Abi-Darghan, A., Van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghi, S.S., et al. (1996) Single photon emission computerized tomography imaging of amphetamine induced dopamine release in drug free schizophrenic subjects Proc. Natl. Acad. Sci. U.S.A. 93, 9235-9240
11. Fletcher, P.C., Frith, C.D., Grasby, P.M., Friston, K.J. & Dolan, R.J. (1996) Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J. Neurosci. 16, 7055-7062
12. Olney, J.W. & Farber, N.B. (1995) Glutamate receptor dysfunction in schizophrenia. Arch. Gen. Psychiatry 52, 998-1007
13. Busatto, G.F. & Kerwin, R.W. (1997) Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia. J. Psychopharmacol. 11, 3-12
14. Harrison, P.J. & Burnet, P.W.J. (1997) The 5-HT2A receptor gene in the aetiology, pathophysiology and therapy of schizophrenia. J. Psychopharmacol. 11, 18-20
15. Chua, S.E. & McKenna, P.J. (1995) Schizophrenia - a brain disease. Br. J. Psychiatry 166, 563-582
16. Ross, C.A. & Pearlson, G.D. (1996) Schizophrenia, the heteromodal association cortex and development potential for a neurogenetic approach. Trends Neurosci. 19 171-176
17. Coon, H., Byerley, W., Holik, J., Hoff, M., Myels-Worsley, M., Lannfelt, L., Sokoloff, P., Schwartz, J.C., Waldo, M., Freedman, R. & Plaetke. R. (1993) Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees. Am. J. Hum. Genet. 52, 327-334
18. Peltonen, L. (1995) All out for chromosome six. Nature (London) 378, 665-666
19. Waddington, J.L. & O'Callaghan, E. (1997) What makes an antipsychotic atypical? Conserving the definition. CNS Drugs 7, 341-346
20. Kane, J.M. (1997) What makes an antipsychotic atypical? Should the definition be preserved? CNS Drugs 7, 347-348
21. Leysen, J.E. & Niemegeers, C.J.E. (1985) Neuroleptics. Handb. Neurochem. 9, 331-361
22. Strange, P.G. (1997) Commentary on atypical neuroleptics. Neurospychopharmacology 16, 116-122
23. 4 receptors. Neuropsychopharmacology 7, 261-284
24. 4 receptor variants in the human population. Nature (London) 358, 149-152
25. 3 receptor. Bioorg. Med. Chem. Lett. 11, 1233-1236
26. 4 receptor antagonist. Trends Pharmacol. Sci. 18, 186-188
27. Duinkerke, S.J., Botter, P.A., Jansen, A.A.I., Van Dongen, P.A.M., Van Haafter, A.J., Boom, A.J., Van Laarhoven, J.H.M. & Busard, H.L.S.M. (1993) Ritanserin, a selective 5-HT2/1C antagonist and negative symptoms in schizophrenia. Br. J. Psychiatry 163, 451-455
28. Meltzer, H.B. (1990) The importance of serotonin-dopamine interactions in the actions of clozapine. Br. J. Psychiatry 160 (Suppl. 17), 22-29
29. Nordstrom, A., Farde, L., Nyberg, S., Karlsson, P., Halldin, C. & Sedvall, G. (1995) D1, D2 and 5HT2 receptor occupancy in relation to clozapine serum concentration. A PET study of schizophrenic patients. Am. J. Psychiatry 152, 1444-1449
30. 2 receptor occupancy during low dose treatment with haloperidol decanoate. Am. J. Psychiatry 152, 173-178
31. Brunello, N., Masotto, C., Steardo, L., Markstein, R. & Racagni, G. (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13, 177-213
32. Pilowsky, L., Mulligan, R.S., Acton, P.D., Eil, P.J., Costa, D.C. & Kerwin, R.W. (1997) Limbic selectivity of clozapine. Lancet 350, 490-491
33. 2 receptors in basal ganglia and cortex of human brain. J. Pharmacol. Exp. Ther. 257, 1253-1263
34. 2 dopamine receptors. Br. J. Pharmacol. 121, 731-736
35. 2 receptors. J. Neurol Transm. 92, 213-220
36. 2L receptor in human embryonic kidney cells. Mol. Pharmacol. 48, 956-964
37. Neve, K.A. & Neve, R.L. (1997) The Dopamine Receptors, Humana Press, Totowa, NJ
38. 3 receptors. Mol. Pharmacol. 43, 749-754
39. Seeman, P. & Van Tol, H.H.M. (1994) Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15, 264-269
40. Seeman, P., Corbett, R. & Van Tol, H.H.M. (1997) Reply to commentaries. Neuropsychopharmacology 16, 127-135